Asymptomatic women with no known risk of ovarian cancer do not benefit from screening for the disease. An update from the U.S. Preventive Services Task Force (USPSTF) retains its previous recommendation against screening in asymptomatic women who are not at high risk for ovarian cancer. The two commonly used screening methods, testing for the serum tumor marker cancer antigen 125 or evaluation with transvaginal ultrasound, have a high number of false-positive results that may lead to unnecessary surgery. And the USPSTF found no evidence to support that such screening reduced mortality from ovarian cancer. The updated recommendation does not apply to women with a family history of ovarian cancer or hereditary cancer risk, such as the gene mutations BRCA1 and BRCA2. The full recommendations, published in JAMA, are at https://jamanetwork.com/journals/jama/fullarticle/2672638.